Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29244745 | 0.88 | HPGD (0.52) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4334069 | 0.88 | HPGD (0.52) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3955730 | 0.85 | HPGD (0.52) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24611623 | 0.85 | HPGD (0.52) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19434590 | 0.85 | HPGD (0.47) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22388002 | 0.84 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2523813 | 0.84 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL21993750 | 0.84 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6498939 | 0.84 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6498946 | 0.84 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| EP-1501495-B1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | NABRIVA THERAPEUTICS AG (AT) | 2010-09-08 | — | — | EP | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| EP-1875903-B1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | NABRIVA THERAPEUTICS AG (AT) | 2010-07-28 | — | — | EP | disclosed |
| EP-1875903-A1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-01-09 | — | — | EP | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20050215637-A1 | Tuberculosis treatment | ASCHER GERD | 2005-09-29 | — | — | US | disclosed |
| US-20050131023-A1 | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2005-06-16 | — | — | US | disclosed |
| EP-1501495-A1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | Sandoz AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1492518-A2 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Sandoz AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003090740-A1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | SANDOZ AG (CH) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003082260-A2 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | SANDOZ AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131023-A1 | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | FABP6, PLEC, UBQLN2 | HPGD 281/4885MEN1 626/4885ALDH1A1 979/4885 |
| US-20050215637-A1 | Tuberculosis treatment | TTR, TST, TREH | HPGD 929/4885MEN1 1178/4885ALDH1A1 797/4885 |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | HPGD 1480/4885MEN1 559/4885ALDH1A1 1152/4885 |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | HPGD 1480/4885MEN1 559/4885ALDH1A1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.